A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safetyof 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508delMutation and a Gating or Residual Function Mutation (F/G and F/RF Ge

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of 445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Ge
StatusFinished
Effective start/end date5/23/191/1/21

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.